Potent SARS-CoV-2 binding and neutralization through maturation of iconic SARS-CoV-1 antibodies

Rouet, Romain; Mazigi, Ohan; Walker, Gregory J.; Langley, David B.; Sobti, Meghna; Schofield, Peter; Lenthall, Helen; Jackson, Jennifer; Ubiparipovic, Stephanie; Henry, Jake Y.; Abayasingam, Arunasingam; Burnett, Deborah; Kelleher, Anthony; Brink, Robert; Bull, Rowena A.; Turville, Stuart; Stewart, Alastair G.; Goodnow, Christopher C.; Rawlinson, William D.; Christ, Daniel

Antibodies against coronavirus spike protein potently protect against infection and disease, however it remains unclear if such protection can be extended to variant coronaviruses. This is exemplified by a set of iconic and well-characterized monoclonal antibodies developed after the 2003 SARS outbreak including mAbs m396, CR3022, CR3014 and 80R, which potently neutralize SARS-CoV-1, but not SARS-CoV-2. Here we explore antibody maturation strategies to change and broaden their specificity, enabling potent binding and neutralization of SARS-CoV-2. Using targeted mutagenesis as well as light chain shuffling on phage, we identified variants with considerably increased affinity and neutralization potential. The most potent antibody, derived from the NIH-developed mAb m396, neutralized live SARS-CoV-2 virus with a half-maximal inhibitory concentration (IC50) of 160 ng/ml. Intriguingly, while many of the matured clones maintained specificity of the parental antibody, new specificities were also observed, which was further confirmed by X-ray crystallography and cryo-electron microscopy, indicating that a limited set of antibodies can give rise to variants targeting diverse epitopes. Our findings open up over 15 years of antibody development efforts against SARS-CoV-1 to the SARS-CoV-2 field and outline general principles for the maturation of antibody specificity against emerging viruses.